KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Notes Payables (2018 - 2024)

Amneal Pharmaceuticals (AMRX) has 5 years of Notes Payables data on record, last reported at $41.9 million in Q1 2024.

  • For Q1 2024, Notes Payables changed N/A year-over-year to $41.9 million; the TTM value through Mar 2024 reached $41.9 million, changed N/A, while the annual FY2023 figure was $41.4 million, 4.38% up from the prior year.
  • Notes Payables reached $41.9 million in Q1 2024 per AMRX's latest filing, up from $41.4 million in the prior quarter.
  • Across five years, Notes Payables topped out at $41.9 million in Q1 2024 and bottomed at $1.0 million in Q1 2020.
  • Average Notes Payables over 4 years is $23.2 million, with a median of $39.7 million recorded in 2022.
  • The widest YoY moves for Notes Payables: up 4.38% in 2023, down 4.38% in 2023.
  • A 4-year view of Notes Payables shows it stood at $1.0 million in 2020, then skyrocketed by 3870.6% to $39.7 million in 2022, then increased by 4.38% to $41.4 million in 2023, then grew by 1.08% to $41.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $41.9 million in Q1 2024, $41.4 million in Q4 2023, and $41.0 million in Q3 2023.